Rockville, Md., July 26, 2018 (Business Wire) -
Linical
and
Accelovance
recently
merged
to create a leading midsized, global contract research organization (CRO) with a significant footprint across North America, Europe and Asia-Pacific. As the next step in the merger, Accelovance has incorporated Linical into its name and will operate as Linical Accelovance Group, which includes Linical Accelovance America, Europe, Romania and China. Additionally,
Vita M. Lanoce, M.S
., has been appointed as chief executive officer of Linical Accelovance Group. Lanoce, previously chief operating officer at Accelovance, has more than 22 years of experience in clinical research at companies including Covance, Synexus (formerly Radiant Research) and Bristol-Myers Squibb. In her new role, Lanoce will oversee all business activities for the Linical Accelovance Group. “The name change is the next step for us to work collaboratively under a shared vision of quality, success, innovation and communication,” said Lanoce. “I look forward to ensuring the continued delivery of robust solutions and personal service, and guiding our collective strengths for enhanced service offerings.” Comprising approximately 925 people across more than 20 countries, Linical is the ideal midsized, global CRO partner for drug developers looking to expand their programs into new markets. The company offers the same reach and experience as larger CROs, yet maintains a personalized, hands-on service approach. The new combined company is capable of conducting studies from early-phase research through large-scale, multinational and late-phase trials. As a one-stop provider for clinical development programs, Linical offers a full scope of flexible solutions and a wide range of therapeutic expertise with specializations in dermatology, immunology, neurology, oncology and vaccines. Linical also demonstrates its oncology expertise through its
HERO™ Project
, which combines its scientific expertise and site networks to accelerate oncology therapeutics to market. Additionally, Linical’s patient engagement solutions are clinical research-focused, enhancing patient recruitment, retention, compliance, surveillance and safety data collection.
About Linical
Linical, a global, midsized contract research organization with a significant footprint across North America, Europe and Asia-Pacific, is the ideal partner for drug developers looking to expand their program into new markets. With operations in more than 20 countries, our global reach makes us uniquely capable of conducting large-scale, multinational studies. At Linical, we deliver a personalized, high-touch service approach across a variety of therapeutic areas and in all phases of development. For more information, visitLinical, a global, midsized contract research organization with a significant footprint across North America, Europe and Asia-Pacific, is the ideal partner for drug developers looking to expand their program into new markets. With operations in more than 20 countries, our global reach makes us uniquely capable of conducting large-scale, multinational studies. At Linical, we deliver a personalized, high-touch service approach across a variety of therapeutic areas and in all phases of development. For more information, visit
Linical.cojp/en/
or
Accelovance.com
.
CONTACT:
Alison Cundari Marketing Manager 803.753.4160
acundari@accelovance.com
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.